Form 4: Armata Pharmaceuticals Director Reports Stock Option Grant

Armata Pharmaceuticals, Inc. director Daniel B. Gilmer reported the acquisition of stock options for 51,280 shares.

Summary

• Director Daniel B. Gilmer of Armata Pharmaceuticals, Inc. has reported the acquisition of stock options.
• The options grant the right to buy 51,280 shares of common stock at an exercise price of $12.92 per share.
• The transaction date was April 24, 2026, and the options have an expiration date of April 24, 2036.
• These stock options vest over three years, with one-third vesting on each annual anniversary of the grant date, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard stock option grant to a director rather than significant financial results or strategic shifts.

Positives

• Director Gilmer has been granted stock options, indicating a potential alignment of management interests with shareholder value.
• The grant of options suggests confidence in the company's future prospects, as their value is tied to the stock price.

Risks

• The value of the stock options is dependent on the future performance of Armata Pharmaceuticals' stock price.
• Vesting is contingent on continuous service, meaning the options could be forfeited if the director leaves the company before vesting.

Future Outlook

The future outlook is implicitly positive as indicated by the grant of stock options, which are typically awarded with the expectation of future stock price appreciation.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the pharmaceutical industry to incentivize performance and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The stock options align director incentives with potential stock price appreciation, which can benefit shareholders if the company performs well.
• Employees: While not directly impacting all employees, the practice of granting options to directors can be seen as part of the broader compensation philosophy that may extend to other employee levels.

Next Steps

• The stock options will vest over three annual anniversaries of the grant date, subject to continuous service.

Key Dates

Keywords

Armata Pharmaceuticals, ARMP, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act